34867302|t|Alleviative Effect of Alpha-Lipoic Acid on Cognitive Impairment in High-Fat Diet and Streptozotocin-Induced Type 2 Diabetic Rats.
34867302|a|Background: The intricate relationship between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) suggests that insulin is involved in modulating AD-related proteins. Alpha-lipoic acid (ALA) can improve insulin resistance (IR) in diabetic rats. However, the role of ALA in alleviating the cognitive decline of T2DM is not yet clear. This study examined the ameliorative effect of ALA on cognitive impairment, cerebral IR, and synaptic plasticity abnormalities in high-fat diet (HFD) plus streptozotocin (STZ) induced diabetic rats. Methods: The HFD/STZ-induced T2DM male Wistar rats were orally administered with ALA (50, 100, or 200 mg/kg BW) once a day for 13 weeks. Abilities of cognition were measured with a passive avoidance test and Morris water maze. Specimens of blood and brain were collected for biochemical analysis after the rats were sacrificed. Western blotting was used to determine protein expressions in the hippocampus and cortex in the insulin signaling pathways, long-term potentiation (LTP), and synaptic plasticity-related protein expressions. Results: Alpha-lipoic acid improved hyperinsulinemia and the higher levels of free fatty acids of the T2DM rats. Behavioral experiments showed that the administration of ALA improved cognitive impairment in HFD/STZ-induced T2DM rats. ALA ameliorated insulin-related pathway proteins [phosphoinositide 3-kinase (PI3K), phospho-protein kinase B (pAkt)/Akt, and insulin-degrading enzyme (IDE)] and the LTP pathway, as well as synaptic plasticity proteins (calmodulin-dependent protein kinase II, cyclic AMP response element-binding protein, and postsynaptic density protein-95) of the cerebral cortex or hippocampus in HFD/STZ-induced T2DM rats. Conclusion: Our findings suggested that ALA may ameliorate cognition impairment via alleviating cerebral IR improvement and cerebral synaptic plasticity in diabetic rats.
34867302	22	39	Alpha-Lipoic Acid	Chemical	MESH:D008063
34867302	43	63	Cognitive Impairment	Disease	MESH:D003072
34867302	85	99	Streptozotocin	Chemical	MESH:D013311
34867302	108	123	Type 2 Diabetic	Disease	MESH:D003924
34867302	124	128	Rats	Species	10116
34867302	177	201	type 2 diabetes mellitus	Disease	MESH:D003924
34867302	203	207	T2DM	Disease	MESH:D003924
34867302	213	232	Alzheimer's disease	Disease	MESH:D000544
34867302	234	236	AD	Disease	MESH:D000544
34867302	286	288	AD	Disease	MESH:D000544
34867302	307	324	Alpha-lipoic acid	Chemical	MESH:D008063
34867302	326	329	ALA	Chemical	MESH:D008063
34867302	343	361	insulin resistance	Disease	MESH:D007333
34867302	363	365	IR	Disease	MESH:D007333
34867302	370	378	diabetic	Disease	MESH:D003920
34867302	379	383	rats	Species	10116
34867302	406	409	ALA	Chemical	MESH:D008063
34867302	429	446	cognitive decline	Disease	MESH:D003072
34867302	450	454	T2DM	Disease	MESH:D003924
34867302	520	523	ALA	Chemical	MESH:D008063
34867302	527	547	cognitive impairment	Disease	MESH:D003072
34867302	558	560	IR	Disease	MESH:D007333
34867302	566	599	synaptic plasticity abnormalities	Disease	MESH:D010411
34867302	628	642	streptozotocin	Chemical	MESH:D013311
34867302	644	647	STZ	Chemical	MESH:D013311
34867302	657	665	diabetic	Disease	MESH:D003920
34867302	666	670	rats	Species	10116
34867302	689	692	STZ	Chemical	MESH:D013311
34867302	701	705	T2DM	Disease	MESH:D003924
34867302	718	722	rats	Species	10116
34867302	753	756	ALA	Chemical	MESH:D008063
34867302	978	982	rats	Species	10116
34867302	1216	1233	Alpha-lipoic acid	Chemical	MESH:D008063
34867302	1243	1259	hyperinsulinemia	Disease	MESH:D006946
34867302	1285	1301	free fatty acids	Chemical	MESH:D005230
34867302	1309	1313	T2DM	Disease	MESH:D003924
34867302	1314	1318	rats	Species	10116
34867302	1377	1380	ALA	Chemical	MESH:D008063
34867302	1390	1410	cognitive impairment	Disease	MESH:D003072
34867302	1418	1421	STZ	Chemical	MESH:D013311
34867302	1430	1434	T2DM	Disease	MESH:D003924
34867302	1435	1439	rats	Species	10116
34867302	1441	1444	ALA	Chemical	MESH:D008063
34867302	1491	1516	phosphoinositide 3-kinase	Gene	298947
34867302	1557	1560	Akt	Gene	24185
34867302	1566	1590	insulin-degrading enzyme	Gene	25700
34867302	1592	1595	IDE	Gene	25700
34867302	1749	1780	postsynaptic density protein-95	Gene	29495
34867302	1827	1830	STZ	Chemical	MESH:D013311
34867302	1839	1843	T2DM	Disease	MESH:D003924
34867302	1844	1848	rats	Species	10116
34867302	1890	1893	ALA	Chemical	MESH:D008063
34867302	1909	1929	cognition impairment	Disease	MESH:D003072
34867302	1955	1957	IR	Disease	MESH:D007333
34867302	2006	2014	diabetic	Disease	MESH:D003920
34867302	2015	2019	rats	Species	10116
34867302	Negative_Correlation	MESH:D008063	MESH:D006946
34867302	Positive_Correlation	MESH:D008063	MESH:D007333
34867302	Positive_Correlation	MESH:D013311	MESH:D003924
34867302	Negative_Correlation	MESH:D008063	MESH:D003920
34867302	Association	MESH:D008063	24185
34867302	Association	MESH:D008063	MESH:D010411
34867302	Positive_Correlation	MESH:D013311	MESH:D003920
34867302	Association	MESH:D008063	25700
34867302	Negative_Correlation	MESH:D008063	MESH:D003072
34867302	Negative_Correlation	MESH:D008063	MESH:D003924
34867302	Negative_Correlation	MESH:D008063	29495
34867302	Negative_Correlation	MESH:D008063	298947
34867302	Association	MESH:D005230	MESH:D003924
34867302	Positive_Correlation	MESH:D005230	MESH:D008063

